albuterol has been researched along with Hay Fever in 24 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 9.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 9.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 9.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "Allergen-induced sneeze, postnasal drip and nasal obstruction were significantly reduced by fluticasone, but not by salmeterol." | 5.12 | Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. ( Fanat, A; O'Byrne, PM; Parameswaran, K, 2006) |
| "AMP nasal provocation produced considerable sneezing and induced a transient increase in histamine and tryptase release with peak values achieved at 3 min after the challenge in all the subjects studied." | 5.11 | Effect of salbutamol on nasal symptoms and mast cell degranulation induced by adenosine 5' monophosphate nasal challenge. ( Guarino, F; Polosa, R; Prosperini, G; Russo, C; Spicuzza, L; Zeng, D, 2005) |
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 5.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 5.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 5.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "Desloratadine is a potent antihistamine." | 2.73 | The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. ( Adalioglu, G; Dizdar, EA; Dogan, C; Kalayci, O; Keskin, O; Sekerel, BE; Tuncer, A, 2007) |
| "Blisters were induced, two on each forearm, by gentle suction and heating, and were unroofed 12 h later, after which plastic chambers were placed over the denuded area." | 2.68 | Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients. ( Grönneberg, R; Halldén, G; Hed, J; Raud, J; van Hage-Hamsten, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.83) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos, MI | 1 |
| Cubillas, JJ | 1 |
| Feito, FR | 1 |
| Prieto, L | 1 |
| Gutiérrez, V | 1 |
| Torres, V | 1 |
| Uixera, S | 1 |
| Marín, J | 1 |
| Baena-Cagnani, CE | 1 |
| Berger, WE | 1 |
| DuBuske, LM | 1 |
| Gurné, SE | 1 |
| Stryszak, P | 1 |
| Lorber, R | 1 |
| Danzig, M | 1 |
| Marogna, M | 1 |
| Falagiani, P | 1 |
| Bruno, M | 1 |
| Massolo, A | 1 |
| Riva, G | 1 |
| Asero, R | 1 |
| Russo, C | 1 |
| Zeng, D | 1 |
| Prosperini, G | 1 |
| Spicuzza, L | 1 |
| Guarino, F | 1 |
| Polosa, R | 1 |
| Parameswaran, K | 1 |
| Fanat, A | 1 |
| O'Byrne, PM | 1 |
| Dizdar, EA | 1 |
| Sekerel, BE | 1 |
| Keskin, O | 1 |
| Kalayci, O | 1 |
| Adalioglu, G | 1 |
| Dogan, C | 1 |
| Tuncer, A | 1 |
| Kupczyk, M | 1 |
| Bogacka, E | 1 |
| Bocheńska-Marciniak, M | 1 |
| Sterchaluk-Grzyb, E | 1 |
| Tworek, D | 1 |
| Kuna, P | 1 |
| González de Olano, D | 1 |
| Trujillo Trujillo, MJ | 1 |
| Santos Magadán, S | 1 |
| Menéndez-Baltanás, A | 1 |
| Gandolfo Cano, M | 1 |
| Ariz Muñoz, S | 1 |
| Sanz Larruga, ML | 1 |
| González-Mancebo, E | 1 |
| Ind, PW | 1 |
| Miyatake, A | 1 |
| Brown, MJ | 1 |
| Dollery, CT | 1 |
| Svenonius, E | 1 |
| Arborelius, M | 1 |
| Kautto, R | 1 |
| Lilja, B | 1 |
| Grant, JA | 1 |
| Nicodemus, CF | 1 |
| Findlay, SR | 1 |
| Glovsky, MM | 1 |
| Grossman, J | 2 |
| Kaiser, H | 1 |
| Meltzer, EO | 1 |
| Mitchell, DQ | 1 |
| Pearlman, D | 1 |
| Selner, J | 1 |
| Di Lorenzo, G | 1 |
| Morici, G | 1 |
| Norrito, F | 1 |
| Mansueto, P | 1 |
| Melluso, M | 1 |
| Purello D'Ambrosio, F | 1 |
| Barbagallo Sangiorgi, G | 1 |
| O'Connor, J | 1 |
| Kane, GC | 1 |
| Tolino, M | 1 |
| Pollice, M | 1 |
| Fish, JE | 2 |
| Peters, SP | 2 |
| Grönneberg, R | 1 |
| van Hage-Hamsten, M | 1 |
| Halldén, G | 1 |
| Hed, J | 1 |
| Raud, J | 1 |
| Hastie, AT | 1 |
| Everts, KB | 1 |
| Shaver, JR | 1 |
| Cirelli, R | 1 |
| Zangrilli, J | 1 |
| Pollice, MB | 1 |
| Leff, AR | 1 |
| Herrnreiter, A | 1 |
| Naclerio, RM | 1 |
| Baroody, FM | 1 |
| Handley, DA | 1 |
| Muñoz, NM | 1 |
| Corren, J | 1 |
| Harris, AG | 1 |
| Aaronson, D | 1 |
| Beaucher, W | 1 |
| Berkowitz, R | 1 |
| Bronsky, E | 1 |
| Chen, R | 1 |
| Chervinsky, P | 1 |
| Cohen, R | 1 |
| Fourre, J | 1 |
| Meltzer, E | 1 |
| Pedinoff, A | 1 |
| Stricker, W | 1 |
| Wanderer, A | 1 |
| Proud, D | 1 |
| Reynolds, CJ | 1 |
| Lichtenstein, LM | 1 |
| Kagey-Sobotka, A | 1 |
| Togias, A | 1 |
| Cohn, JR | 1 |
| Sataloff, RT | 1 |
| Branton, C | 1 |
| Lidington, RE | 1 |
| Cotton, DJ | 1 |
| Graham, BL | 1 |
| Dosman, JA | 1 |
| Jorde, W | 1 |
| Bohlmann, HG | 1 |
| Linsenmann, P | 1 |
| Werdermann, K | 1 |
| Vignale, L | 1 |
| Parentini, GC | 1 |
| Rossi, PC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
11 trials available for albuterol and Hay Fever
| Article | Year |
|---|---|
Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol | 2002 |
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm | 2003 |
Effect of salbutamol on nasal symptoms and mast cell degranulation induced by adenosine 5' monophosphate nasal challenge.
Topics: Adenosine Monophosphate; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory A | 2005 |
Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Allergi | 2006 |
The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis.
Topics: Adolescent; Albuterol; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Bronchodilator Agents; | 2007 |
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho | 2005 |
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Asthma; Cetirizine; Double-Blind Method; Ephedrine; Humans; Male; Plac | 1995 |
Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.
Topics: Adult; Albuterol; Asthma; Blood Proteins; Cell Count; Cross-Over Studies; Eosinophil Granule Protein | 1995 |
Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients.
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Adult; Albuterol; Blister; Dermatitis, Atopic; | 1996 |
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E | 1997 |
Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration.
Topics: Administration, Intranasal; Adrenergic beta-Agonists; Albuterol; Asthma; Capillary Permeability; Cel | 1998 |
13 other studies available for albuterol and Hay Fever
| Article | Year |
|---|---|
Improvement of the Prediction of Drugs Demand Using Spatial Data Mining Tools.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Child; Child, Preschoo | 2016 |
The allergic march in pollinosis: natural history and therapeutic implications.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; Coho | 2004 |
Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients.
Topics: Adult; Age Factors; Aged; Albuterol; Allergens; Ambrosia; Asthma; Betula; Bronchodilator Agents; Fem | 2004 |
Anaphylaxis to salbutamol.
Topics: Adult; Albuterol; Anaphylaxis; Drug Hypersensitivity; Erythema; Female; Humans; Immunoglobulin E; Rh | 2008 |
Do human mast cells possess functional beta adrenoceptors in vivo?
Topics: Adult; Albuterol; Asthma; Female; Histamine; Histamine Release; Humans; Male; Mast Cells; Propranolo | 1983 |
Lung function studies in children with allergic rhinitis.
Topics: Adolescent; Albuterol; Child; Exercise Test; Functional Residual Capacity; Humans; Maximal Midexpira | 1982 |
Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Antigens; Asthma; Bronchial | 1995 |
Beta 2-agonist-elevated stress response in human bronchial epithelial cells in vivo and in vitro.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Biopsy; Bronchi; Bronchial Provocatio | 1997 |
Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils.
Topics: Adrenergic beta-Agonists; Albuterol; Eosinophil Peroxidase; Eosinophils; Humans; Immunoglobulin E; N | 1997 |
Response of asthma-related voice dysfunction to allergen immunotherapy: a case report of confirmation by methacholine challenge.
Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Desensitization, Immunol | 2001 |
Peripheral airways obstruction in patients with rhinitis.
Topics: Adult; Airway Obstruction; Albuterol; Female; Forced Expiratory Volume; Humans; Male; Maximal Midexp | 1979 |
[Protective effect of beta-adrenergic substances on the allergic rhinitis (author's transl)].
Topics: Airway Resistance; Albuterol; Humans; Metaproterenol; Phenols; Rhinitis, Allergic, Seasonal; Time Fa | 1975 |
[Evaluation of the bronchial tonus, basal and following bronchodilators, in subjects with allergic rhinitis].
Topics: Adolescent; Adult; Albuterol; Bronchi; Bronchodilator Agents; Female; Forced Expiratory Volume; Huma | 1989 |